Search Results for: 19

Theriva™ Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

– Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) – April 13, 2023 08:00 ET ROCKVILLE, Md., April 13, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), (“Theriva” or the “Company”), a diversified clinical-stage company developing therapeutics designed to treat cancer […]

Theriva™ Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Theriva Biologics anuncia la presentación de los datos de la cohorte 1 del ensayo clínico de fase Ib/IIa de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas

– Los datos provisionales de farmacocinética y seguridad con enmascaramiento se presentarán en el 33.er Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas (ECCMID) – April 13, 2023 16:25 ET ROCKVILLE, Maryland, April 13, 2023 (GLOBE NEWSWIRE) — Theriva Biologics (NYSE American: TOVX), («Theriva» o la «Empresa»), una empresa diversificada de fase clínica que investiga

Theriva Biologics anuncia la presentación de los datos de la cohorte 1 del ensayo clínico de fase Ib/IIa de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas Read More »

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022

March 31, 2023 00:33 ET – Dosis al primer paciente de VIRAGE, un ensayo clínico de fase 2b de VCN-01 administrado sistémicamente en combinación con quimioterapia en el adenocarcinoma ductal pancreático – – Dosis al primer paciente del ensayo de fase 1 patrocinado por investigadores de VCN-01 en pacientes con tumores cerebrales – – Presentación

Theriva Biologics presenta los aspectos operativos más destacados y los resultados financieros del cuarto trimestre y del ejercicio 2022 Read More »

Theriva™ Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

March 30, 2023 08:00 ET – Dosed the first patient in VIRAGE, a Phase 2b clinical trial of systemically administered VCN-01 in combination with chemotherapy for Pancreatic Ductal Adenocarcinoma – – Dosed the first patient in the investigator sponsored Phase 1 clinical trial of VCN-01 for patients with brain tumors – – Presented positive safety

Theriva™ Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results Read More »

Theriva™ Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

February 16, 2023 12:05 ET – Data presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR – – Analysis of patients receiving meropenem suggest that SYN-004 is well-tolerated with HCT and was not observed in blood samples from the majority of the evaluable patients – ROCKVILLE, Md., Feb. 16,

Theriva™ Biologics Announces Presentation of Safety and Pharmacokinetic Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients Read More »

Theriva Biologics anuncia la presentación de los datos de seguridad de uso y farmacocinética de la cohorte 1 del ensayo clínico de fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas

February 16, 2023 12:05 ET – Datos presentados en los Tandem Meetings 2023: Reuniones sobre trasplantes y terapias celulares de la ASTCT y el CIBMTR – – Los análisis de los pacientes que recibieron meropenem sugieren que SYN-004 se tolera bien con HCT y no se observó en las muestras de sangre de la mayoría

Theriva Biologics anuncia la presentación de los datos de seguridad de uso y farmacocinética de la cohorte 1 del ensayo clínico de fase 1b/2a de SYN-004 (ribaxamasa) en receptores de trasplantes alogénicos de células hematopoyéticas Read More »

Contact

Want to learn more? We’d love to hear from you. US Headquarters 9605 Medical Center Dr. Suite 270 Rockville, MD 20850 European Office Theriva™ Biologics SL Carrer Torrent de Can Ninou, naus 5-6 08150 – Parets del Vallès (Barcelona) Spain Email info@therivabio.com

Contact Read More »

Careers

WORK AT THERIVA™ As we grow, we continue to seek talented and driven scientists, marketers, analysts, and engineers who share in our mission. We are a collaborative, generous, and committed team that is devoted to leveraging the unique perspectives of every team member in our efforts to develop first-in-class cancer therapies. While there are no

Careers Read More »

Our Pipeline

OVERVIEW Theriva™ Biologics’ oncolytic viruses have the potential to treat a broad range of difficult-to-treat tumor types and may be combined with a variety of cancer therapies. In the on-going VIRAGE Phase 2 clinical trial in patients with PDAC, VCN-01 is being tested in combination with standard-of-care chemotherapy gemcitabine/nab-paclitaxel. VCN-01 was also administered with the

Our Pipeline Read More »